Skip to main content
Innoviva, Inc. logo

Innoviva, Inc. — Investor Relations & Filings

Ticker · INVA ISIN · US45781M1018 LEI · 549300ACOX4QTBES6535 US Financial and insurance activities
Open in API
Filings indexed 1,226 across all filing types
Latest filing 2017-04-12 Proxy Solicitation & In…
Country US United States of America
Listing US INVA

About Innoviva, Inc.

https://www.inva.com/

Innoviva, Inc. is a diversified holding company that manages a portfolio of royalty-generating assets and operates a commercial-stage biopharmaceutical platform. The company's core royalty business is centered on respiratory therapies, providing a stable cash flow. Through its subsidiary, Innoviva Specialty Therapeutics, it focuses on developing and commercializing innovative treatments for patients in critical care and with infectious diseases. Innoviva's strategy involves leveraging its financial assets to invest in healthcare opportunities with high unmet medical needs, aiming to advance differentiated therapies and build a diverse portfolio of healthcare assets.

Recent filings

Filing Released Lang Actions
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a definitive proxy statement pursuant to Section 14(a) of the Securities Exchange Act of 1934. It contains detailed information urging shareholders to vote for the board nominees, discusses the company's strategy, and includes forward-looking statements and financial reconciliations. The presence of the term 'Proxy Statement' and the SEC form type 'DEFA14A' clearly indicates this is a proxy solicitation document. Proxy statements are classified under Proxy Solicitation & Information Statement (PSI). The document is not an annual report, earnings release, or other financial report but rather materials sent to shareholders to provide information and request votes for meetings.
2017-04-12 English
DFAN14A
Proxy Solicitation & Information Statement
2017-04-11 English
DFAN14A
Proxy Solicitation & Information Statement
2017-04-10 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is used for current reports on significant events. The text specifically mentions a capital return program and prepayment of $50 million on royalty notes, which relates to financing activities. The document is short (2508 characters) and includes a press release as an exhibit. The content focuses on a financing update rather than a full financial report or earnings release. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2017-04-10 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a definitive proxy statement or additional materials related to a proxy solicitation for a shareholder meeting. It discusses board nominees, voting recommendations, and shareholder meeting details. It is not an annual report, earnings release, or financial statement. The document is clearly a proxy solicitation material, which corresponds to the Proxy Solicitation & Information Statement category (PSI). The document length is over 10,000 characters and contains detailed information about the proxy contest and board nominees, consistent with a PSI filing rather than a brief announcement or regulatory filing.
2017-04-10 English
DFAN14A
Proxy Solicitation & Information Statement
2017-04-10 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.